Abstract
Compared the risk of tuberculosis in 264 patients who received high active antiretroviral therapy (HAART) in phase III clinical trials and a prospective cohort of 770 non-HAART patients who were attending Somerset Hospital adult HIV clinic, University of Cape Town, between 1992 and 2001. Found that HAART reduced the incidence of HIV-1-associated tuberculosis by more than 80% in an area endemic with tuberculosis and HIV-1. The protective effect of HAART was greatest in symptomatic patients and those with advanced immune suppression. (Original abstract - amended)